Adverse Events Following Yellow Fever Vaccination in Korean Children.
- Author:
Jae Yo LEE
1
;
Tae Hee KIM
;
Hyang Mi PARK
;
Hye Jung SHIN
;
Kyeung Eun KIM
;
Sang Taek LEE
;
Jae Yoon KIM
Author Information
1. Department of Pediatrics, National Medical Center, Seoul, Korea. nmcmpkjy@unitel.co.kr
- Publication Type:Original Article
- Keywords:
Yellow Fever;
Yellow Fever Vaccine;
Adverse events
- MeSH:
Abdominal Pain;
Child;
Cough;
Fever;
Headache;
Hemorrhagic Fevers, Viral;
Humans;
Interviews as Topic;
Male;
Prospective Studies;
Risk Factors;
Vaccination;
Vomiting;
Yellow Fever;
Yellow Fever Vaccine
- From:Korean Journal of Pediatric Infectious Diseases
2009;16(1):54-60
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE:Yellow fever, a mosquito-borne viral hemorrhagic fever, is one of the most lethal diseases. Recently there have been an increasing number of Korean children who have travelled to yellow fever endemic zones and were administered yellow fever vaccine (YFV). Therefore, we carried out this study to provide child travelers with safety information of YFV. METHODS:This study was conducted at the International Clinic of National Medical Center in Seoul between April 2007 and June 2008 for the evaluation of adverse events of YFV. One hundred twenty- five children received YFV (17-DD) and were prospectively monitored for adverse events through telephone interviews on day 3, 6, 9, 16, 23 and 30 after vaccination. RESULTS:Adverse events were observed in 31 (24.8%) of 125 child travelers who received the YFV. The mean age was 12.5+/-5.0 years. Sixty-six of the child travelers (52.8%) were males. The common adverse events were pain in 11 (8.8%), swelling in 8 (6.4%) and redness in 7 children (5.6%) at the injection site. The systemic adverse events included mild fever in 5 (4.0%), headache in 5 (4.0%), cough in 4 (3.2%), abdominal pain in 3 (2.4 %), and vomiting in 2 children (1.6%). Most of the adverse events were detected within 7 days of administration and there were no differences in adverse events by gender or age. All travelers who had complained of symptoms improved spontaneously or following symptomatic treatment. CONCLUSION:This study showed that YFV is well-tolerated and there were no reports of severe adverse events. Studies are ongoing to clarify the cause and risk factors for rare adverse events.
